Jiangsu Lianhuan Completes Enrollment for Phase III Study of LH-1801 in Type 2 Diabetes
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) has announced the completion of subject enrollment...
Diabetes
Novo Nordisk Launches Rybelsus in China, World’s First Oral GLP-1RA
Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced the commercial launch of its innovative...
CSPC’s Prusogliptin Approved in China for Type 2 Diabetes Treatment
China’s National Medical Products Administration (NMPA) has granted marketing approval to CSPC Pharmaceutical Group Co.,...
Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes
Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...
Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management
US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...
Shanghai Pharmaceuticals Halts Development of I001-B, I022, and C012 in the US
China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials...
Corxel Pharmaceuticals Secures Global Rights to CX11, a Novel Oral GLP-1 RA, in Licensing Deal with Vincentage
China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing...
Hansoh Pharmaceutical Secures Global Licensing Deal with Merck for HS-10535
China’s Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced a significant global license deal...
Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study
China-based Gan & Lee Pharmaceuticals (SHA: 603087) has announced that it has received approval from...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Clearance for HRS-4729 Peptide Drug
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced the receipt of clinical clearance from...
Hua Medicine’s Second-Generation GKA HM-002-1005 Completes Phase Ia Study in the US
China-based Hua Medicine (HKG: 2552) has announced the successful completion of a Phase Ia study...
Hua Medicine’s SENSITIZE Study Illuminates Dorzagliatin’s β-Cell Glucose Sensitivity Mechanism
China-based innovative drug developer Hua Medicine (HKG: 2552), with operations in the US and Hong...
China Medical System Holdings Gets NMPA Approval to Test Obesity Treatment CMS-D005
China Medical System Holdings Ltd (CMS, HKG: 0867) has announced that it has received approval...
Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105
China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by China’s NMPA for Type 2 Diabetes
China-based Sciwind Biosciences Co., Ltd has announced that the National Medical Products Administration (NMPA) has...
Hua Medicine and Bayer AG Terminate Co-promotion Agreement for HuaTangNing
China-based Hua Medicine (HKG: 2552) has announced the termination of its co-promotion agreement with German...
Medtronic Receives US Approval for InPen App with Missed Meal Dose Detection
US-Irish firm Medtronic (NYSE: MDT) has announced US market approval for its new InPen app,...
Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its...
Eli Lilly’s Tirzepatide Shows Sustained Weight Loss in 176-Week Study
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has released 176-week follow-up data from...
Zucara Therapeutics Secures $20M Series B Financing Led by Sanofi and PXV Fund
Canada-based diabetes life sciences company, Zucara Therapeutics Inc., has announced the receipt of a strategic...